Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer
暂无分享,去创建一个
E. V. Van Allen | G. Ha | C. Pritchard | S. Salipante | C. Morrissey | E. Corey | N. De Sarkar | M. Schweizer | Jared M. Lucas | M. Haffner | P. Nelson | R. Dumpit | S. Frank | Michael C. Haffner | P. Chatterjee | Sayan Dasgupta | B. Hanratty | Talina A. Nunez | Lisa S. Ang | Ilsa Coleman | R. Montgomery | Radhika A. Patel | Emily A. Kohlbrenner
[1] Robert Brown,et al. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer , 2020, Modern Pathology.
[2] Henry W. Long,et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer , 2020, Nature Communications.
[3] Xin Lu,et al. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage , 2020, The Prostate.
[4] C. Higano,et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Oza,et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. , 2020, The Lancet. Oncology.
[6] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[7] W. Hahn,et al. ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer , 2020, Cancer Research.
[8] F. Feng,et al. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study , 2020, Clinical Cancer Research.
[9] Z. Szallasi,et al. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations , 2020, Clinical Cancer Research.
[10] N. Tunariu,et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial , 2019, The Lancet. Oncology.
[11] P. Nelson,et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. , 2019, The Journal of clinical investigation.
[12] M. Morgan,et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. , 2019, The New England journal of medicine.
[13] Romina Royo,et al. A practical guide for mutational signature analysis in hematological malignancies , 2019, Nature Communications.
[14] N. Socci,et al. Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.
[15] Yi Mi Wu,et al. Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.
[16] Isidro Cortés-Ciriano,et al. Detecting the mutational signature of homologous recombination deficiency in clinical samples , 2019, Nature Genetics.
[17] M. Gleave,et al. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity , 2019, Molecular Cancer Research.
[18] C. Caldas,et al. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation , 2018, EMBO molecular medicine.
[19] Z. Szallasi,et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer , 2018, npj Breast Cancer.
[20] Joshua M. Stuart,et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.
[21] Martin A. M. Reijns,et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions , 2018, Nature.
[22] Nicholas D. Camarda,et al. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. , 2018, Cancer discovery.
[23] A. Chinnaiyan,et al. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer , 2018, Cell.
[24] Ville Mustonen,et al. The repertoire of mutational signatures in human cancer , 2018, Nature.
[25] Yi Mi Wu,et al. The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.
[26] M. Stratton,et al. Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells , 2018, Nature.
[27] Richard A. Moore,et al. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer , 2017, Clinical Cancer Research.
[28] J. Reis-Filho,et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes , 2017, Nature Communications.
[29] Z. Szallasi,et al. The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.
[30] E. Lander,et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.
[31] O. Rueda,et al. BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity , 2017, EMBO molecular medicine.
[32] H. Wu,et al. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] Ruedi Aebersold,et al. A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability , 2017, Cell.
[34] E. Birney,et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.
[35] P. Nelson,et al. LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.
[36] R. Simon,et al. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness , 2016, EMBO reports.
[37] Ahmet Zehir,et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.
[38] P. Nelson,et al. Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.
[39] Z. Szallasi,et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.
[40] J. Shendure,et al. Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.
[41] B. Taylor,et al. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.
[42] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[43] Paola Lecca,et al. SPOP mutation leads to genomic instability in prostate cancer , 2015, eLife.
[44] David C. Smith,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[45] A. Richardson,et al. BRCA1 haploinsufficiency for replication stress suppression in primary cells , 2014, Nature Communications.
[46] Nicolai J. Birkbak,et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] Rafael A. Irizarry,et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..
[48] Mauricio O. Carneiro,et al. From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.
[49] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[50] Robert Gentleman,et al. Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..
[51] Yair Goldberg,et al. FEATURE ELIMINATION IN KERNEL MACHINES IN MODERATELY HIGH DIMENSIONS. , 2013, Annals of statistics.
[52] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[53] A. Børresen-Dale,et al. Copynumber: Efficient algorithms for single- and multi-track copy number segmentation , 2012, BMC Genomics.
[54] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[55] John Quackenbush,et al. Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome , 2012, Clinical Cancer Research.
[56] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[57] Jernej Ule,et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. , 2011, Genes & development.
[58] Hiroyuki Konishi,et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells , 2011, Proceedings of the National Academy of Sciences.
[59] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[60] A. Ashworth,et al. A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.
[61] J.C. Rajapakse,et al. SVM-RFE With MRMR Filter for Gene Selection , 2010, IEEE Transactions on NanoBioscience.
[62] O. Johannsson,et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes , 2009, Breast Cancer Research.
[63] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[64] A. DeMarzo,et al. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation , 2006, Nucleic acids research.
[65] A. D'Amico,et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] J Isola,et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.
[67] Journal Cell,et al. A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability , 2017 .
[68] Anne Floquet,et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[69] H. Hieronymus,et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. , 2014, Neoplasia.
[70] Alan Ashworth,et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. , 2014, Cancer research.
[71] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..